Email this article 
Updates of Congenital Cytomegalovirus (cCMV) infection: Literature Review
Abstract
Congenital cytomegalovirus (cCMV) infection is the most well-known congenital viral disease and is the main non-genetic reason for sensorineural hearing loss (SNLH) and a significant reason for neurodevelopmental inabilities. The gamble of intrauterine transmission is most elevated when vertical infection happens during pregnancy, with a higher pace of vertical transmission in mothers with more established gestational age at infection, while the gamble of unfriendly fetal impacts fundamentally increments on the adverse effects that fetal infection happens during the first half of pregnancy. Although, its prevalence and morbidity among the neonatal populace, there isn't yet a standardised diagnostic test and therapeutic methodology for cCMV infection. This review expects to investigate the most recent improvements in the diagnosis and treatment of cCMV infection. literature shows that preventive interventions other than behavioural measures during pregnancy are as yet lacking, albeit numerous clinical preliminaries are right now progressing to plan vaccination for women before pregnancy. As of now, we suggest utilizing a PCR measure in blood, urine, and saliva in neonates with suspected cCMV infection. As of now, there is no proof of the advantage of antiviral treatment in asymptomatic infants. On account of symptomatic cCMV, we really suggest treatment with oral valganciclovir for a length of a year. The adequacy and tolerability of this treatment choice have demonstrated successful for hearing and neurodevelopmental long-term results. Valganciclovir is saved for congenitally infected neonates with the symptomatic infection at birth, like microcephaly, intracranial calcifications, unusual cerebrospinal fluid index, chorioretinitis, or sensorineural hearing loss. Treatment with antiviral medications isn't regularly recommended for neonates with the mildly symptomatic infection at birth, for neonates under 32 weeks of gestational age, or for infants over 30 days old due to deficient proof from studies. In any case, since these populaces represent by far most of neonates and infants with cCMV disease and they are in risk of developing late-onset sequelae, a biomarker ready to foresee long-term sequelae ought to likewise be found to justify beginning treatment and decreasing the burden of CMV-related complications.
Keywords
Full Text:
PDFReferences
Liesnard, Corinne, et al. "Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk." Obstetrics & Gynecology 95.6 (2000): 881-888.
Manicklal, Sheetal, et al. "The “silent” global burden of congenital cytomegalovirus." Clinical microbiology reviews26.1 (2013): 86-102.
Buxmann, Horst, et al. "Primary human cytomegalovirus (HCMV) infection in pregnancy." Deutsches Ärzteblatt International 114.4 (2017): 45.
Kalser, Julia, et al. "Differences in growth properties among two human cytomegalovirus glycoprotein O genotypes." Frontiers in microbiology 8 (2017): 1609.
Kenneson, Aileen, and Michael J. Cannon. "Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection." Reviews in medical virology 17.4 (2007): 253-276.
Lanzieri, Tatiana M., et al. "Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries." International Journal of Infectious Diseases 22 (2014): 44-48.
Boppana, Suresh B., Shannon A. Ross, and Karen B. Fowler. "Congenital cytomegalovirus infection: clinical outcome." Clinical infectious diseases 57. suppl_4 (2013): S178-S181.
Morton, Cynthia C., and Walter E. Nance. "Newborn hearing screening—a silent revolution." New England Journal of Medicine 354.20 (2006): 2151-2164.
Barton, Michelle, A. Michael Forrester, and Jane McDonald. "Update on congenital cytomegalovirus infection: Prenatal prevention, newborn diagnosis, and management." Paediatrics & Child Health 25.6 (2020): 395-395.
Boppana, Suresh B., et al. "Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity." New England Journal of Medicine 344.18 (2001): 1366-1371.
Bodéus, Monique, Corinne Hubinont, and Patrick Goubau. "Increased risk of cytomegalovirus transmission in utero during late gestation." Obstetrics & Gynecology 93.5 (1999): 658-660.
Enders, Gisela, et al. "Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age." Journal of Clinical Virology 52.3 (2011): 244-246.
Pass, Robert F., et al. "Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome." Journal of clinical virology 35.2 (2006): 216-220.
de Vries, Jutte JC, et al. "The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population‐based prediction model." Reviews in medical virology 23.4 (2013): 241-249.
Foulon, Ina, et al. "Hearing loss in children with congenital cytomegalovirus infection in relation to the maternal trimester in which the maternal primary infection occurred." Pediatrics122.6 (2008): e1123-e1127.
Thigpen, Jim. "Congenital Cytomegalovirus—History, Current Practice, and Future Opportunities." Neonatal Network 39.5 (2020): 293-298.
Johnson, Julie M., and Brenna L. Anderson. "Cytomegalovirus: should we screen pregnant women for primary infection?" American journal of perinatology 30.02 (2013): 121-124.
Goderis, Julie, et al. "Hearing loss and congenital CMV infection: a systematic review." Pediatrics 134.5 (2014): 972-982.
Dahle, Arthur J., et al. "Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus." Journal of the American Academy of Audiology 11.05 (2000): 283-290.
Joint Committee on Infant Hearing, and Joint Committee on Infant Hearing. "Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. 2007 Retrieved June 20, 2014."
Yoshinaga‐Itano, Christine. "Early intervention after universal neonatal hearing screening: impact on outcomes." Mental retardation and developmental disabilities research reviews9.4 (2003): 252-266.
Dollard, Sheila C., Scott D. Grosse, and Danielle S. Ross. "New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection." Reviews in medical virology 17.5 (2007): 355-363.
Coats, David K., et al. "Ophthalmologic findings in children with congenital cytomegalovirus infection." Journal of American Association for Pediatric Ophthalmology and Strabismus 4.2 (2000): 110-116.
del Cotone, Magazzini, and Metodologie Biofisiche. "PROGRAMMA FINALE." (2013).
Lim, Yinru, and Hermione Lyall. "Congenital cytomegalovirus–who, when, what-with and why to treat?" Journal of Infection74 (2017): S89-S94.
Chiopris, Giulia, et al. "Congenital cytomegalovirus infection: update on diagnosis and treatment." Microorganisms 8.10 (2020): 1516.
Rawlinson, William D., et al. "Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy." The Lancet Infectious Diseases 17.6 (2017): e177-e188.
Luck, Suzanne E., et al. "Congenital cytomegalovirus: a European expert consensus statement on diagnosis and management." The Pediatric infectious disease journal 36.12 (2017): 1205-1213.
Wang, Chengbin, et al. "Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection." Clinical infectious diseases 52.2 (2011): e11-e13.
Townsend, Claire L., et al. "Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom." Clinical Infectious Diseases 56.9 (2013): 1232-1239.
Guerra, Brunella, et al. "Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers." American journal of obstetrics and gynecology 196.3 (2007): 221-e1.
Adler, Stuart P. "Screening for cytomegalovirus during pregnancy." Infectious diseases in obstetrics and gynecology2011 (2011).
Messinger, Chelsea J., et al. "Association between congenital cytomegalovirus and the prevalence at birth of microcephaly in the United States." JAMA pediatrics 174.12 (2020): 1159-1167.
Vauloup-Fellous, Christelle, et al. "Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital." Journal of Clinical Virology 46 (2009): S49-S53.
Cordier, A. G., et al. "Awareness of cytomegalovirus infection among pregnant women in France." Journal of clinical virology53.4 (2012): 332-337.
Pereboom, Monique TR, et al. "Observational study to assess pregnant women’s knowledge and behaviour to prevent toxoplasmosis, listeriosis and cytomegalovirus." BMC pregnancy and childbirth 13.1 (2013): 1-12.
Binda, Sandro, et al. "What people know about congenital CMV: an analysis of a large heterogeneous population through a web-based survey." BMC infectious diseases 16.1 (2016): 1-11.
Prince, Harry E., and Mary Lapé-Nixon. "Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy." Clinical and Vaccine Immunology 21.10 (2014): 1377-1384.
LAZZAROTTO, TIZIANA, et al. "Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus." Viral immunology 13.1 (2000): 137-141.
Kekkou, Kassiani, et al. "Risk of congenital cytomegalovirus infection in children born to women with IgG avidity in the grey zone during first trimester of pregnancy." The Journal of Maternal-Fetal & Neonatal Medicine 34.12 (2021): 2025-2029.
Furione, Milena, et al. "False human cytomegalovirus IgG-positivity at prenatal screening." Journal of Clinical Virology104 (2018): 34-38.
Lazzarotto, Tiziana, et al. "Congenital cytomegalovirus infection: a narrative review of the issues in screening and management from a panel of European experts." Frontiers in pediatrics (2020): 13.
Guerra, Brunella, et al. "Ultrasound prediction of symptomatic congenital cytomegalovirus infection." American journal of obstetrics and gynecology 198.4 (2008): 380-e1.
Guerra, Brunella, et al. "Prenatal diagnosis of symptomatic congenital cytomegalovirus infection." American journal of obstetrics and gynecology 183.2 (2000): 476-482.
Zavattoni, Maurizio, et al. "Monitoring of human cytomegalovirus DNAemia during primary infection in transmitter and non-transmitter mothers." Journal of Clinical Virology 82 (2016): 89-93.
Simonazzi, Giuliana, et al. "Congenital cytomegalovirus infection: prognostic value of maternal DNAemia at amniocentesis." Clinical Infectious Diseases 64.2 (2017): 207-210.
Enders, M., et al. "Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience." Prenatal Diagnosis 37.4 (2017): 389-398.
Farkas, Natalie, et al. "Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection?" Prenatal diagnosis 31.4 (2011): 360-366.
Faure‐Bardon, V., et al. "Refining the prognosis of fetuses infected with Cytomegalovirus in the first trimester of pregnancy by serial prenatal assessment: a single‐centre retrospective study." BJOG: An International Journal of Obstetrics & Gynaecology 127.3 (2020): 355-362.
Picone, Olivier, et al. "Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection." Prenatal diagnosis 28.8 (2008): 753-758.
Lipitz, S., et al. "Risk of cytomegalovirus‐associated sequelae in relation to time of infection and findings on prenatal imaging." Ultrasound in Obstetrics & Gynecology 41.5 (2013): 508-514.
Leruez-Ville, Marianne, et al. "Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis." American journal of obstetrics and gynecology 215.3 (2016): 342-e1.
Enders, Gisela, et al. "Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome." Prenatal diagnosis 21.5 (2001): 362-377.
Luck, S. E., et al. "Compartmentalized dynamics of cytomegalovirus replication in treated congenital infection." Journal of Clinical Virology 82 (2016): 152-158.
Barbi, Maria, et al. "Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection." Journal of clinical virology 17.3 (2000): 159-165.
Yamamoto, Aparecida Yulie, et al. "Usefulness of blood and urine samples collected on filter paper in detecting cytomegalovirus by the polymerase chain reaction technique." Journal of virological methods 97.1-2 (2001): 159-164.
Yamamoto, Aparecida Yulie, et al. "Is saliva as reliable as urine for detection of cytomegalovirus DNA for neonatal screening of congenital CMV infection?" Journal of clinical virology 36.3 (2006): 228-230.
Nozawa, Naoki, et al. "Real-time PCR assay using specimens on filter disks as a template for detection of cytomegalovirus in urine." Journal of clinical microbiology 45.4 (2007): 1305-1307.
Soetens, Oriane, et al. "Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for analysis of dried blood spots from consecutive cases of neonates with congenital CMV infections." Journal of Clinical Microbiology46.3 (2008): 943-946.
Boppana, Suresh B., et al. "Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection." Jama 303.14 (2010): 1375-1382.
Boppana, Suresh B., et al. "Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns." New England Journal of Medicine 364.22 (2011): 2111-2118.
Ross, Shannon A., et al. "Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens." The Journal of infectious diseases 210.9 (2014): 1415-1418.
Ross, Shannon A., et al. "Newborn dried blood spot PCR to identify infants with congenital cytomegalovirus-associated sensorineural hearing loss." The Journal of pediatrics 184 (2017): 57.
Ross, Shannon A., et al. "Urine collection method for the diagnosis of congenital cytomegalovirus infection." The Pediatric infectious disease journal 34.8 (2015): 903.
de Vries, Jutte JC, et al. "Real-time PCR versus viral culture on urine as a gold standard in the diagnosis of congenital cytomegalovirus infection." Journal of Clinical Virology 53.2 (2012): 167-170.
Koyano, Shin, et al. "Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study." BMJ open 1.1 (2011): e000118.
Barbi, Maria, et al. "Diagnosis of congenital cytomegalovirus infection by detection of viral DNA in dried blood spots." Clinical and diagnostic virology 6.1 (1996): 27-32.
Hugo Johansson, P. J., et al. "Retrospective diagnostics of congenital cytomegalovirus infection performed by polymerase chain reaction in blood stored on filter paper." Scandinavian journal of infectious diseases 29.5 (1997): 465-468.
Marsico, Concetta, and David W. Kimberlin. "Congenital Cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment." Italian journal of pediatrics 43.1 (2017): 1-8.
Wang, Li, et al. "Dried blood spots PCR assays to screen congenital cytomegalovirus infection: a meta-analysis." Virology journal 12 (2015): 1-11.
Barbi, Maria, Sandro Binda, and Simona Caroppo. "Diagnosis of congenital CMV infection via dried blood spots." Reviews in medical virology 16.6 (2006): 385-392.
Pellegrinelli, Laura, et al. "Diagnosing congenital Cytomegalovirus infection: don’t get rid of dried blood spots." BMC Infectious Diseases 20 (2020): 1-5.
Walter, Simone, et al. "Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss." Archives of Disease in Childhood-Fetal and Neonatal Edition 93.4 (2008): F280-F285.
Pellegrinelli, Laura, et al. "Diagnosis of congenital CMV infection via DBS samples testing and neonatal hearing screening: an observational study in Italy." BMC Infectious Diseases 19 (2019): 1-5.
Marsico, Concetta, et al. "Blood viral load in symptomatic congenital cytomegalovirus infection." The Journal of Infectious Diseases 219.9 (2019): 1398-1406.
Smiljkovic, Mina, et al. "Blood viral load in the diagnostic workup of congenital cytomegalovirus infection." Journal of Clinical Virology 122 (2020): 104231.
Forner, Gabriella, et al. "High Cytomegalovirus (CMV) DNAemia predicts CMV sequelae in asymptomatic congenitally." (2014).
Bradford, Russell D., et al. "Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system." Journal of Infectious Diseases 191.2 (2005): 227-233.
Section on Breastfeeding, et al. "Breastfeeding and the use of human milk." Pediatrics 129.3 (2012): e827-e841.
Hamprecht, Klaus, and Rangmar Goelz. "Postnatal cytomegalovirus infection through human milk in preterm infants: transmission, clinical presentation, and prevention." Clinics in perinatology 44.1 (2017): 121-130.
Stagno, Sergio, et al. "Breast milk and the risk of cytomegalovirus infection." New England Journal of Medicine302.19 (1980): 1073-1076.
Pilar, Romero‐Gómez Maria, et al. "Evaluation of cytomegalovirus infection in low–birth weight children by breast milk using a real‐time polymerase chain reaction assay." Journal of medical virology 87.5 (2015): 845-850.
Jim, Wai-Tim, et al. "Outcome of preterm infants with postnatal cytomegalovirus infection via breast milk: a two-year prospective follow-up study." Medicine 94.43 (2015).
Bardanzellu, Flaminia, Vassilios Fanos, and Alessandra Reali. "Human breast milk-acquired cytomegalovirus infection: certainties, doubts and perspectives." Current pediatric reviews 15.1 (2019): 30-41.
Pass, Robert F., and Brenna Anderson. "Mother-to-child transmission of cytomegalovirus and prevention of congenital infection." Journal of the Pediatric Infectious Diseases Society3.suppl_1 (2014): S2-S6.
Schleiss, Mark R. "Cytomegalovirus vaccines under clinical development." Journal of virus eradication 2.4 (2016): 198-207.
Pass, Robert F., et al. "Vaccine prevention of maternal cytomegalovirus infection." New England Journal of Medicine360.12 (2009): 1191-1199.
Sabbaj, Steffanie, et al. "Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women." Journal of Infectious Diseases 203.11 (2011): 1534-1541.
Schleiss, Mark R., et al. "Vaccination with a live attenuated cytomegalovirus devoid of a protein kinase R inhibitory gene results in reduced maternal viremia and improved pregnancy outcome in a guinea pig congenital infection model." Journal of virology 89.19 (2015): 9727-9738.
Price, Simani M., et al. "Educating women about congenital cytomegalovirus: assessment of health education materials through a web-based survey." BMC Women's Health 14.1 (2014): 1-10.
Johnson, Julie, Brenna Anderson, and Robert F. Pass. "Prevention of maternal and congenital cytomegalovirus infection." Clinical obstetrics and gynecology 55.2 (2012): 521.
Kimberlin, David W., et al. "Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial." The Journal of pediatrics 143.1 (2003): 16-25.
Oliver, Sara E., et al. "Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system." Journal of Clinical Virology 46 (2009): S22-S26.
Kimberlin, David W., et al. "Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease." The Journal of infectious diseases 197.6 (2008): 836-845.
Kimberlin, David W., et al. "Valganciclovir for symptomatic congenital cytomegalovirus disease." New England Journal of Medicine 372.10 (2015): 933-943.
Bilavsky, Efraim, et al. "Hearing outcome of infants with congenital cytomegalovirus and hearing impairment." Archives of disease in childhood 101.5 (2016): 433-438.
Gwee, Amanda, et al. "Ganciclovir for the treatment of congenital cytomegalovirus: what are the side effects?" The Pediatric infectious disease journal 33.1 (2014): 115.
Sijmons, Steven, et al. "High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination." Journal of virology 89.15 (2015): 7673-7695.
Fu, Tong-Ming, et al. "Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus." Vaccine30.52 (2012): 7469-7474.
Wang, Dai, et al. "A replication-defective human cytomegalovirus vaccine for prevention of congenital infection." Science translational medicine 8.362 (2016): 362ra145-362ra145.
Adler, Stuart P., et al. "Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects." The Journal of infectious diseases 220.3 (2019): 411-419.
Murata, Shinya, et al. "Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study." Antibodies 12.1 (2023): 22.
Merck, S., and C. Dohme. "Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-Center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3—Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age; Clinical Trial Registration NCT03486834. 2021." (2021).
Gonczol, Eva, et al. "Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers." Vaccine 8.2 (1990): 130-136.
Pass, Robert F., et al. "A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant." The Journal of infectious diseases 180.4 (1999): 970-975.
Ott, Gary, et al. "Design and evaluation of a safe and potent adjuvant for human vaccines." Vaccine Design, The Subunit and Adjuvant Approach (1995): 227-296.
Frey, Sharon E., et al. "Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine." The Journal of infectious diseases 180.5 (1999): 1700-1703.
Mitchell, Douglas K., et al. "Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers." The Pediatric infectious disease journal 21.2 (2002): 133-138.
Pass, Robert F., et al. "Vaccine prevention of maternal cytomegalovirus infection." New England Journal of Medicine 360.12 (2009): 1191-1199.
Sabbaj, Steffanie, et al. "Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women." Journal of Infectious Diseases 203.11 (2011): 1534-1541.
Griffiths, Paul D., et al. "Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial." The Lancet 377.9773 (2011): 1256-1263.
Bernstein, David I., et al. "Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial." Vaccine 34.3 (2016): 313-319.
La Rosa, Corinna, et al. "MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults." Blood, The Journal of the American Society of Hematology 129.1 (2017): 114-125.
Aldoss, Ibrahim, et al. "Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial." Annals of internal medicine 172.5 (2020): 306-316.
La Rosa, Corinna, et al. "CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients after Stem Cell Transplant." 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Tandem Meetings, 2023.
Majewska, Anna, and Beata Mlynarczyk-Bonikowska. "40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?" International journal of molecular sciences 23.7 (2022): 3431.
Plotkin, Stanley A., and Suresh B. Boppana. "Vaccination against the human cytomegalovirus." Vaccine 37.50 (2019): 7437-7442.
Scarpini, Sara, et al. "Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice." Vaccines 9.6 (2021): 551.
Schwendinger, Michael, et al. "A randomized dose-escalating phase I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine against human cytomegalovirus." The Journal of Infectious Diseases 225.8 (2022): 1399-1410.
Schwendinger, Michael, et al. "A randomized dose-escalating phase I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine against human cytomegalovirus." The Journal of Infectious Diseases 225.8 (2022): 1399-1410.
Hookipa Biotech GmbH. "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Seropositive Donors (D+).; Clinical Trial Registration NCT03629080." (2021).
Schleiss, Mark R., Sallie R. Permar, and Stanley A. Plotkin. "Progress toward development of a vaccine against congenital cytomegalovirus infection." Clinical and Vaccine Immunology24.12 (2017): e00268-17.
Rosa, Corinna La, et al. "Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries." Blood, The Journal of the American Society of Hematology 97.6 (2001): 1776-1786.
Sylwester, Andrew W., et al. "Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects." The Journal of experimental medicine 202.5 (2005): 673-685.
Zaia, John A., et al. "Infrequent Occurrence of Natural Mutations in the pp65495–503 Epitope Sequence Presented by the HLA A∗ 0201 Allele among Human Cytomegalovirus Isolates." Journal of virology 75.5 (2001): 2472-2474.
Wloch, Mary K., et al. "Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects." Journal of Infectious Diseases 197.12 (2008): 1634-1642.
La Rosa, Corinna, et al. "Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant." Journal of Infectious Diseases 205.8 (2012): 1294-1304.
Gratama, Jan W., et al. "Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study." Blood, The Journal of the American Society of Hematology 116.10 (2010): 1655-1662.
Kirchmeier, Marc, et al. "Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity." Clinical and Vaccine Immunology 21.2 (2014): 174-180.
August, Allison, et al. "A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age." Vaccine 35.30 (2017): 3749-3759.
Selinsky, C., et al. "A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases." Human Vaccines 1.1 (2005): 16-23.
Smith, Larry R., et al. "Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial." Vaccines 1.4 (2013): 398-414.
Kharfan-Dabaja, Mohamed A., et al. "A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial." The Lancet infectious diseases 12.4 (2012): 290-299.
Astellas Pharma Global Development, Inc. "A randomized, double‐blind, placebo‐controlled, phase 3 trial to evaluate the protective efficacy and safety of a therapeutic vaccine, ASP0113, in cytomegalovirus (CMV)‐seropositive recipients undergoing allogeneic, Hematopoietic Cell Transplant (HCT)." ClinicalTrials. gov [Internet] (2000).
Ljungman, Per, et al. "A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients." EClinicalMedicine33 (2021): 100787.
Vincenti, Flavio, et al. "A randomized, phase 2 study of ASP 0113, a DNA‐based vaccine, for the prevention of CMV in CMV‐seronegative kidney transplant recipients receiving a kidney from a CMV‐seropositive donor." American Journal of Transplantation 18.12 (2018): 2945-2954.
Scarpini, Sara, et al. "Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice." Vaccines 9.6 (2021): 551.
Pardi, Norbert, et al. "Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination." Nature543.7644 (2017): 248-251.
Leppek, Kathrin, et al. "Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics." Nature communications 13.1 (2022): 1536.
Brito, Luis A., et al. "A cationic nanoemulsion for the delivery of next-generation RNA vaccines." Molecular Therapy 22.12 (2014): 2118-2129.
John, Shinu, et al. "Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity." Vaccine 36.12 (2018): 1689-1699.
Scarpini, Sara, et al. "Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice." Vaccines 9.6 (2021): 551.
August, Allison, et al. "A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age." Vaccine 35.30 (2017): 3749-3759.
Chu, Laurence, et al. "A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine." Vaccine 39.20 (2021): 2791-2799.
Sommerer, Claudia, et al. "Peptide Vaccination Against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients." Vaccines 9.2 (2021): 133
Nigro, Giovanni, et al. "Passive immunization during pregnancy for congenital cytomegalovirus infection." Obstetrical & gynecological survey 61.3 (2006): 155-156.
Revello, Maria Grazia, et al. "A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus." New England Journal of Medicine 370.14 (2014): 1316-1326.
Hughes, Brenna L. "Randomized trial to prevent congenital cytomegalovirus." American Journal of Obstetrics & Gynecology 221.6 (2019): 670-671.
Thürmann, P. A., C. Sonnenburg-Chatzopoulos, and R. Lissner. "Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation." European journal of clinical pharmacology 49 (1995): 237-242.
Hamprecht, Klaus, Karl-Oliver Kagan, and Rangmar Goelz. "Hyperimmune globulin to prevent congenital CMV infection." N Engl J Med 370.26 (2014): 2543.
Kagan, K. O., et al. "Prevention of maternal–fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration." Ultrasound in Obstetrics & Gynecology 53.3 (2019): 383-389.
DOI: http://dx.doi.org/10.52155/ijpsat.v38.1.5263
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Maged Naser
This work is licensed under a Creative Commons Attribution 4.0 International License.